MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A legfontosabb adatok
- Ki végzi
- University of Pennsylvania
- Hol
- Philadelphia (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 46 fő vett részt
- Kezdés
- 2018. okt. 24.
- Befejezés
- 2024. márc. 26.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoport
- A vizsgált kezelések
- MOv19-BBz CAR T cells
- Alpha Folate Receptor expression test
- A regiszteradat frissítve
- 2025. március 26.
- Miért állt le
- This study was halted prematurely due to recruitment barriers
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (26)A regiszter feltételeinek elrejtése
Ki vehet részt
- Histologically confirmed persistent or recurrent stage II to IV high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Disease can be platinum-sensitive or platinum-resistant
- Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible
- Confirmation of tumor aFR expression (≥70% of tumor cells with ≥2+ aFR staining)
- Subjects must have measureable disease as defined by RECIST 1.1 criteria
- Patients with asymptomatic CNS metastases that have been treated and are off steroids are allowed. They must meet the following at the time of eligibility confirmation by physician-investigator:; No concurrent treatment for the CNS disease; No progression of CNS metastasis on brain MRI at screening; No evidence of leptomeningeal disease or cord compression
- Patients ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Satisfactory organ and bone marrow function as defined by the following:; Absolute neutrophil count ≥ 1,000/μl ii. Platelets ≥75,000/μl iii. Hemoglobin ≥ 9 g/dL iv. Total bilirubin ≤ 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine ≤ 1.5x the institutional normal upper limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit viii. Cardiac ejection fraction of ≥40%
- Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT ≤ 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters
- Provides written informed consent
- Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3
Ki nem vehet részt
- Participation in a therapeutic investigational study within 4 weeks prior to eligibility confirmation by physician-investigator, or anticipated treatment with another investigational product while on study. This refers to non-commercially approved investigational drugs different than those used in this protocol
- Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (<10 mg daily equivalent of prednisone). Corticosteroids treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional guidance. The use of topical and/or inhaled steroids are not exclusionary
- Patients requiring supplemental oxygen therapy
- Prior therapy with lentiviral gene modified cells
- Any ascites requiring therapeutic drainage within 4 weeks prior to eligibility confirmation by physician-investigator
- High grade serous ovarian, fallopian, or primary peritoneal cancer that is platinum refractory, defined as disease that has clinical or radiographic progression on platinum-based chemotherapy, as per the discretion of the treating physician
- Active invasive cancer other than ovarian cancers. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder cancer) are not excluded
- HIV infection
- Hepatitis B or hepatitis C infection
- Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to >/= 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as multiple sclerosis) will be excluded
- Patients with active and uncontrolled infection
- Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the physician-investigator, would make the patient inappropriate for entry into the study
- History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)
- Patients with symptomatic CNS metastases are excluded
- Pregnant or breastfeeding women
Helyszínek itt: Egyesült Államok
- University of Pennsylvania Health SystemPhiladelphia, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy
A vizsgálat 4 csoportja
- Cohort 1: MOv19-BBz CAR T cells without chemoA vizsgált kezelés
Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
Kezelés: MOv19-BBz CAR T cells és Alpha Folate Receptor expression test
- Cohort 2: MOv19-BBz CAR T cells after chemoA vizsgált kezelés
Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
Kezelés: MOv19-BBz CAR T cells és Alpha Folate Receptor expression test
- Cohort 3: MOv19-BBz CAR T cells after chemoA vizsgált kezelés
Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
Kezelés: MOv19-BBz CAR T cells és Alpha Folate Receptor expression test
- Cohort-1: without chemo;only if dose de-escalation requiredA vizsgált kezelés
Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
Kezelés: MOv19-BBz CAR T cells és Alpha Folate Receptor expression test
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Publikációk
- A regiszteradat frissítve
- 2025. március 26.